Suppr超能文献

腺苷受体激活可调节家兔的眼压。

Adenosine receptor activation modulates intraocular pressure in rabbits.

作者信息

Crosson C E

机构信息

Department of Ophthalmology and Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, USA.

出版信息

J Pharmacol Exp Ther. 1995 Apr;273(1):320-6.

PMID:7714784
Abstract

The relatively selective adenosine A1 agonists N6-cyclohexy-ladenosine (CHA), R(-)-N6-(2-phenylisopropyl)adenosine (R-PIA) and S(+)-N6-(2-phenylisopropyl)adenosine (S-PIA); the A2a agonist 2-p-carboxyethyl)phenethyl-amino-5'-N-ethylcarbox-amidoadenosin e (CGS-21680) and the nonselective A2 agonist 2-phenylaminoadenosine (CV-1808) were evaluated in vivo for their effects on aqueous humor dynamics and in vitro for their action on 3H-norepinephrine release and cAMP accumulation in the isolated iris/ciliary body. These studies demonstrated that adenosine agonists can modulate intraocular pressure (IOP). Except for CV-1808, the topical administration of adenosine agonists produced a unilateral dose-related reduction in IOP with a potency order of R-PIA = CHA > CGS-21680 > S-PIA > CV-1808. Although CV-1808 did not lower IOP, it did induce a significant dose-dependent rise in IOP. Neither the reduction in IOP induced by R-PIA nor the rise in IOP induced by CV-1808 was affected by surgical removal of the superior cervical ganglion. However, the adenosine agonist-induced reduction in IOP was associated with a significant decrease in aqueous flow. In vitro studies demonstrated that the adenosine agonists did not alter the evoked release of 3H-norepinephrine; however, they were effective in suppressing the accumulation of cAMP, and this response was blocked by pretreatment with the antagonist 8-cyclopentyl-1,3-dimethylxanthine. These studies provide evidence that adenosine agonists lower IOP by activating postjunctional adenosine A1 receptors. This response is associated with a reduction in aqueous flow and the modulation of cAMP in the iris/ciliary body.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对相对选择性的腺苷A1激动剂N6-环己基腺苷(CHA)、R(-)-N6-(2-苯异丙基)腺苷(R-PIA)和S(+)-N6-(2-苯异丙基)腺苷(S-PIA);A2a激动剂2-对羧乙基)苯乙氨基-5'-N-乙基羧酰胺腺苷(CGS-21680)以及非选择性A2激动剂2-苯氨基腺苷(CV-1808)进行了体内评估,观察它们对房水动力学的影响,并在体外评估它们对分离的虹膜/睫状体中3H-去甲肾上腺素释放和环磷酸腺苷(cAMP)积累的作用。这些研究表明,腺苷激动剂可调节眼压(IOP)。除CV-1808外,局部应用腺苷激动剂可使IOP产生单侧剂量相关的降低,其效力顺序为R-PIA = CHA > CGS-21680 > S-PIA > CV-1808。虽然CV-1808不会降低IOP,但它确实会引起IOP显著的剂量依赖性升高。R-PIA引起的IOP降低和CV-1808引起的IOP升高均不受颈上神经节手术切除的影响。然而,腺苷激动剂引起的IOP降低与房水流量的显著减少有关。体外研究表明,腺苷激动剂不会改变诱发的3H-去甲肾上腺素释放;然而,它们可有效抑制cAMP的积累,并且该反应可被拮抗剂8-环戊基-1,3-二甲基黄嘌呤预处理所阻断。这些研究提供了证据,表明腺苷激动剂通过激活节后腺苷A1受体来降低IOP。这种反应与房水流量减少以及虹膜/睫状体中cAMP的调节有关。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验